Company news

Puma Biotechnology Inc news in 2020

Puma Biotechnology Inc's news releases, calls and decks from 2020, newest first.

View company

Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS

December 10, 2020

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

December 8, 2020

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

December 1, 2020

Puma Biotechnology Reports Third Quarter 2020 Financial Results

November 4, 2020

Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

November 4, 2020

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

October 4, 2020

Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology

August 18, 2020

Puma Biotechnology Reports Second Quarter 2020 Financial Results

August 5, 2020

Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers

July 26, 2020

Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results

July 22, 2020

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer

July 15, 2020

Puma Biotechnology Reports First Quarter 2020 Financial Results

May 6, 2020

Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea

April 29, 2020

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

March 24, 2020

Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer

February 25, 2020

Decks in 2020